VA-DXC-TECHNOLOGY
25.2.2020 15:02:10 CET | Business Wire | Press release
DXC Technology (NYSE: DXC) today highlighted how it is helping enterprises accelerate the adoption of augmented reality (AR), virtual reality (VR) and mixed reality (MR) technologies to support immersive experiences in ways that can significantly improve productivity, quality and efficiency.
According to Gartner, by 2022, 70% of enterprises will be experimenting with immersive technologies for consumer and enterprise use, and 25% will have deployed them to production.* DXC is using AR, VR and MR technologies today to transform the future of work, and the company is seeing widespread implementation to improve safety, connect remote workers, assist with complex tasks and enhance training and collaboration – all in ways that drive business results and profitability.
“Digital transformation in the workplace is edging towards an inflection point as enterprises are incorporating immersive solutions that connect the real world with the virtual world,” said Maria Pardee, DXC’s senior vice president and general manager, Workplace and Mobility. “DXC is using the power of AR, VR and MR to align the next-generation digital capabilities employees want so they can be more mobile and independent, with the critical security, production prowess and agility that today’s businesses demand.”
DXC Deploys Mixed Reality Employee Training at Water Treatment Leader Ixom
A market leader in water treatment and chemical distribution in Australia and New Zealand, Ixom turned to DXC to develop a custom training and assessment application using mixed reality on Microsoft HoloLens.
In the past, Ixom training and learning assessments were conducted at customer sites, requiring travel, scheduling and employee resources to mitigate safety risks. Now, using DXC’s mixed reality application for Microsoft HoloLens — custom built for Ixom — employees can participate in the required training and learning assessment at any Ixom office or remote location. The resulting increase in flexibility, autonomy and mobility has reduced Ixom travel costs, minimized employee safety risks and essentially eliminated the potential for exposure to hazardous materials during training at treatment facilities.
DXC is named a Leader in Advanced Digital Workplace Services Overall in the NelsonHall Evaluation & Assessment Tool (NEAT) Report 2019 . DXC is also an official partner in the Microsoft HoloLens Mixed Reality Partner Program, a status that reflects the company’s commitment to designing, developing and deploying solutions that help customers accelerate their digital transformations using mixed reality technologies.
The following DXC offerings enable immersive solutions using AR/VR technologies:
- DXC AR/VR services consist of AR/VR consulting, custom application development and system integration for a range of AR/VR devices including Microsoft HoloLens. DXC is also a Distributor Managed Partner for HoloLens 2 and provides services for MR business applications such as Microsoft Dynamics 365 Guides.
- DXC Remote Expert is an innovative AR solution that enables field workers in various industries (automotive, energy and utilities, manufacturing, travel and transportation, and healthcare) to display work instructions via a hands-free interface on their wearable or mobile devices and connect to experts at other locations when they need guidance.
- DXC Unified Endpoint Management enables enterprises to manage and secure mobile, PC, internet-of-things (IoT) and wearable devices in a single pane of glass. DXC’s collaboration with industry-leading technology partners, combined with DXC transformation, delivery and support services, provides users with secure and seamless access to enterprise applications, data and services independent of operating system, device type or location.
- DXC Workplace IoT enables enterprises to securely deploy and manage smart connected devices by combining IoT solutions, best practices, and market-leading platforms and technology partners to improve production, operational and human outcomes; automate processes with analytics; and gain situational awareness.
- DXC Open Health Connect creates a connected ecosystem that optimizes services for patients, healthcare providers and payers, using AR to provide better patient outcomes.
*Smarter With Gartner, Top 10 Strategic Technology Trends for 2019, October 2019, https://www.gartner.com/smarterwithgartner/gartner-top-10-strategic-technology-trends-for-2019 .
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005245/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom